Can we reduce the dosage of biologics in spondyloarthritis?

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 691-693

  Olivieri, Ignazio ^a   D'Angelo, Salvatore ^a,b   Padula, Angela ^a   Leccese, Pietro ^a   Nigro, Angelo ^a   Palazzi, Carlo ^a  

^a San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Ankylosing spondylitis; Psoriatic arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; HUMAN; PSORIATIC ARTHRITIS; RELAPSE; REMISSION; REVIEW; SPONDYLARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84877823834     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.08.013     Document Type: Review

References (43)

1. Amor B., Dougados M., Mijiyawa M. Critères de classification des spondylarthropathies. Rev Rhum Mal Osteoartic 1990, 57:85-89.
2. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1228-1230.
3. Davis J.C., van der Heijde D., Braun J., Dougados M., Cush J., Clegg D.O., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236.
4. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
5. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
6. Inman R.D., Davis J.C., van der Heijde D., Diekman L., Sieper J., Kim S.I., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58:3402-3412.
7. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
8. Kavanaugh A., Antoni C.E., Gladman D., Wassenberg S., Zhou B., Beutler A., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1year. Ann Rheum Dis 2006, 65:1038-1043.
9. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289.
10. Kavanaugh A., McInnes I., Mease P., Krueger G.G., Gladman D., Gomez-Reino J., et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986.
11. Ballanti E., Perricone C., di Muzio G., Kroegler B., Chimenti M.S., Graceffa D., et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors review article. Autoimmun Rev 2011, 10(10):617-623.
12. Maksymowych W.P. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010, 6:75-81.
13. Sieper J., Appel H., Braun J., Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implication for treatment outcomes. Arthritis Rheum 2008, 58:649-656.
14. Elkayam O., Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012, 12:329-336.
15. Goekoop-Ruiteman Y.P.M., de Vries-Bouwstra J.K., Allart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized controlled study. Arthritis Rheum 2008, 58(Suppl. 2):S126-S135.
16. Tanaka Y., Takeuchi T., Mimori T., Saito K., Nawata M., Kameda H., et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010, 69:1286-1291.
17. Baraliakos X., Listing J., Brandt J., Zink A., Alten R., Burmester G., et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3years of continuous treatment with infliximab. Arthritis Res Ther 2005, 7:R439-R444.
18. Baraliakos X., Listing J., Rudwaleit M., Brandt J., Alten R., Burmester G., et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007, 34:510-515.
19. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.
20. Brandt J., Listing J., Haibel H., Sörensen H., Schwebig A., Rudwaleit M., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005, 44:342-348.
21. Navarro-Compán V., Moreira V., Ariza-Ariza R., Hernández-Cruz B., Vargas-Lebrón C., Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011, 30:993-996.
22. Lee J., Noh J.W., Hwang J.W., Oh J.M., Kim H., Ahn J.K., et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010, 29:1149-1154.
23. Rudwaleit M., van der Heijde D., Landewé R., Listing J., Akkoc N., Brandt J., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
24. Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R.L., Kupper H., et al. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58:1981-1991.
25. Barkham N., Keen H.I., Coates L.C., O'Connor P., Hensor E., Fraser A.D., et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60:946-954.
26. Song I.H., Hermann K., Haibel H., Althoff C.E., Listing J., Burmester G., et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011, 70:590-596.
27. Sieper J., van der Heijde D., Dougados M., Mease P., Brown L.S., Pangan A. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis-results from a phase 3 study. Presented at the 2011 ACR/ARPH Annual Meeting. Chicago, IL USA November 5-9 2011, (abstract 2486A).
28. Song I.H., Althoff C.E., Haibel H., Hermann K.G., Poddubnyy D., Listing J., et al. Frequency and duration of drug-free remission after 1year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2year data of the ESTHER trial. Ann Rheum Dis 2012, 71:1212-1215.
29. Rudwaleit M., van der Heijde D., Landewé R., Listing J., Akkoc N., Brandt J., et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
30. Brandt J., Haibel H., Reddig J., Sieper J., Braun J. Successful treatment of severe undifferentiated spondyloarthropathy with anti-tumor necrosis factor α monoclonal antibody infliximab. J Rheumatol 2002, 29:118-122.
31. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Rudwaleit M., et al. Successful treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor α receptor fusion protein etanercept. J Rheumatol 2004, 31:531-538.
32. Dougados M., Combe B., Braun J., Landewé R., Sibilla J., Cantragel A., et al. A randomized, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010, 69:1430-1435.
33. Palazzi C., Padula A., Montaruli M., Pennese E., Olivieri I. Pharmacologic management of undifferentiated spondyloarthropathies. Exp Opin Rheumatol 2006, 15:39-46.
34. Olivieri I., Giasi V., Scarano E., Gigliotti P., D'Angelo S., Padula A. A brief course of anti-TNF-α therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis. Clin Exp Rheumatol 2009, 27:1057.
35. Olivieri I., Scarano E., Padula A., D'Angelo S., Cantini F. Switching TNFα inhibitors may also be useful in HLA-B27-associated severe heel enthesitis. Arthritis Rheum 2007, 57:1572-1574.
36. Olivieri I., Scarano E., Gigliotti P., Giasi V., Padula A. Successful treatment of juvenile onset HLA-B27 associated severe and refractory heel enthesitis with adalimumab. Rheumatology (Oxford) 2006, 45:1315-1317.
37. Chimenti M.S., Graceffa D., Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission?. Autoimmun Rev 2011, 10:636.
38. Gladman D.D., Hing E.N., Schentag C.T., Cook R.J. Remission in psoriatic arthritis. J Rheumatol 2001, 28:1045-1048.
39. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42:1460-1468.
40. Pinals R.S., Masi A.T., Larsen R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308-1315.
41. Cantini F., Niccoli L., Nannini C., Cassarà E., Pasquetti P., Olivieri I., et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 2008, 47:872-876.
42. Saber T.P., Ng C.T., Renard G., Lynch B.M., Pontifex E., Walsh C.A., et al. Remission in psoriatic arthritis: is it possible and how can it be predicted?. Arthritis Res Ther 2010, 12:R94.
43. Thayer S., Watson C., Song R., Globe D.R., Harrison D.J. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ 2010, 13:228-235.